INBS Secures $5M Private Placement with Warrants Contingent on FDA 510(k) Clearance
INBS sits 63% above its 52-week low of $1.52.
Summary
Intelligent Bio Solutions raised $5 million in a private placement of pre-funded warrants and two series of common stock warrants, with the N-1 warrants callable only after FDA 510(k) clearance of its drug screening system.
Key Events · Financing and Capital Events · INBS
-
$5M Private Placement Closed
Sold 2,036,659 pre-funded warrants plus Series N-1 and N-2 warrants at $2.455 per unit for approximately $5.0 million gross proceeds, closing September 2, 2026.
-
Warrant Structure Tied to FDA Clearance
Series N-1 warrants (2,036,659 shares at $2.33) are exercisable immediately and callable by the company only after FDA 510(k) clearance of the Intelligent Fingerprinting Drug Screening System; Series N-2 warrants require shareholder approval.
-
Potential Dilution
If all pre-funded warrants and N-1/N-2 warrants are exercised, up to 6,109,977 additional shares could be issued — a highly dilutive outcome for a company with a market cap near $7.5 million.
-
Placement Agent Compensation
Ladenburg Thalmann received 8% cash fee, 1% management fee, 9% on warrant exercises, 5% warrant coverage (101,833 shares at $3.06875), and up to $145,000 expense reimbursement.
Analysis · INBS · Industrial Applications And Services
A $5 million private placement closed on September 2, 2026, with Intelligent Bio Solutions selling 2,036,659 pre-funded warrants plus Series N-1 and N-2 warrants at $2.455 per unit. For a company with a market cap near $7.5 million, the deal is highly dilutive — the pre-funded warrants alone represent a substantial portion of the outstanding share count, and the N-1 and N-2 warrants could add up to 4,073,318 more shares if exercised. The N-1 warrants are callable by the company only after FDA 510(k) clearance of its fingerprint drug screening system, tying the financing directly to the regulatory milestone the company has been pursuing all year. Ladenburg Thalmann received 8% cash, 1% management, 9% on warrant exercises, 5% warrant coverage, and up to $145,000 in expense reimbursement. The company has a going concern warning from its August 19, 2026 10-K, so this capital extends runway but at significant cost to existing shareholders.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBS was trading at $2.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.